The effect of Esomeprazole to asthma control in asthma patients with GERD taking inhaled corticosteroid

The effect of Esomeprazole to asthma control in asthma patients with GERD taking inhaled corticosteroid - The effect of PPI in asthmatics with GERD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011811

Enrollment

Registered

2013-09-19

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma with gastroesophageal reflux disease(GERD)

Interventions

Asthmatics with GERD are treated with Esomeprazole (EPZ)(20mg) daily for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: In patients with bronchial asthma, all of the following criteria was required for enrollment (1)age:20 years or more (2)receiving inhaled corticosteroid for at least 4 weeks (3)diagnosed with GERD by Gerd Q or FSSG

Exclusion criteria

Exclusion criteria: (1)hypersensitivity to EPZ or other PPI (2)treated with atazanavir sulfate (3)hypersensitivity to drugs (4)severe disease in liver, kidney, heart (5)severe symptom in gastrointestinal tract(hematemesis, hemorrhagic stool, severe anemia, sudden weight loss) (6)past history of gastrointestinal tract resection, vagotomy, lung resection (7)in combination with other PPI or histamine H2 antagonist (8)not treated with systemic steroid for 3 months before the enrollment (9)decided to be unsuitable to enrollment by physician

Design outcomes

Primary

Measure	Time frame
The change of %FEV1 12 weeks after the introduction of EPZ.	—

Countries

Japan

Contacts

Public ContactShintaro Miyamoto

Kochi University School of Medicine Department of Hematology and Respiratory Medicine

miyamoto@kochi-u.ac.jp088-880-2345

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026